SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Political uncertainty ahead of the midterm elections and debate over the Iran conflict dominate discussion, with traders linking war and cost-of-living concerns to market pressure and DJTs decline. Bearish views prevail, though some speculate a peace deal or Republican win could improve sentiment.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is drawing attention as traders react to Iran-related tensions and reported threats to oil shipments through the Strait of Hormuz, which have fueled concerns about supply disruptions and supported crude prices. Bulls see further risk from possible escalation and depleted reserves, while bears expect a sharp pullback if negotiations produce a deal or tensions ease.

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.

AbCellera Biologics Inc

Attention centers on ABCL635, AbCelleras antibody for menopausal hot flashes: traders are discussing its positive Phase 2 results and additional conference data while watching for longer-term durability results and clarity on a Phase 3 path. Bulls view the program as validation of AbCelleras pipeline, while skeptics say the latest presentation added little beyond known results and want more concrete clinical updates.

Select Sector SPDR Trust (The) - State Street Energy Select Sector SPDR ETF

Energy Select Sector SPDR Fund

Traders are focused on the Iran conflict, Strait of Hormuz shipping risks and reported attacks on energy infrastructure, with concerns about disrupted oil and fuel supply supporting interest in energy stocks. The community is split between those expecting further gains if tensions persist and those warning that diplomacy, easing supply fears or profit-taking could reverse the rally.

ProShares Trust II - ProShares Ultra Bloomberg Crude Oil 2x Shares

ProShares Ultra Bloomberg Crude Oil

Hopes for U.S.-Iran de-escalation are weighing on crude prices and UCO, while persistent concerns about Strait of Hormuz disruptions and constrained supply keep some traders bullish. The community is debating whether diplomacy will ease the oil-risk premium or whether renewed conflict will sustain sharp swings.

Marvell Technology, Inc. engages in the design, development, and sale of integrated circuits. Its products include data processing units, security solutions, automotive, coherent DSP, DCI optical modules, ethernet controllers, ethernet PHYs, ethernet switches, linear driver, PAM DSP, transimpedance amplifiers, fibre channel, HDD, SSD controller, storage accelerators, ASIC, and Marvell government solutions. It operates through the following geographical segments: United States, Singapore, Israel, India, China, and Others. The company was founded by Wei Li Dai and Pantas Sutardja in 1995 and is headquartered in Wilmington, DE.

Marvell Technology Inc

Reports of advanced talks to acquire Lumentum have driven attention, with traders worried the large deal could require substantial share dilution or debt and weigh on Marvell. Some see strategic value in combining Marvells AI networking chips with Lumentums optical technology, but the talks remain unconfirmed and the market reaction has been sharply negative.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Metas negative S&P outlook, tied to heavy AI infrastructure spending and uncertainty about free cash flow, is driving concern alongside fears that planned stock sales could dilute shareholders. Traders debate whether strong advertising growth and potential AI monetization can justify the investment, with some viewing the selloff as a buying opportunity.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantirs upcoming Q3 report is the dominant focus, with traders debating whether strong results and raised guidance can clear an already high bar as AI stocks face a broader pullback. Bulls expect continued growth, while skeptics warn that a beat may not prevent selling given the stocks lofty valuation and risk-off sentiment.

ProShares Trust II - ProShares Ultra Bloomberg Natural Gas 2x Shares

ProShares Ultra Bloomberg Natural Gas

BOIL is drawing attention as natural-gas weakness and repeated lows collide with hopes for a winter-weather rebound. Traders disagree over whether colder forecasts and tighter storage could spark a bounce, while others point to mild-weather expectations, ample supply, and the ETFs leverage and futures-roll decay as risks.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

A breakout to a 52-week high has fueled buyout speculationoften centered on Sanofiand hopes for a short squeeze, with traders also pointing to heavy call-option activity. BRIUMVIs commercial growth and forthcoming earnings and subcutaneous data add to the optimism, while some traders doubt a deal is imminent and see the rally as momentum ahead of results.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Abbott's TECTONIC clinical trial demonstrates strong 30-day outcomes and high procedural success for its investigational SonicForce Coronary Intravascular Lithotripsy System

Abbott's TECTONIC clinical trial demonstrates strong 30-day outcomes and high procedural success for its investigational SonicForce Coronary Intravascular Lithotripsy System Abbott's TECTONIC clinical trial demonstrates strong 30-day outcomes and high procedural success for its investigational...

Abbott initiates pivotal trial for Cephea device, an innovative treatment for mitral heart valve disease

Abbott initiates pivotal trial for Cephea device, an innovative treatment for mitral heart valve disease Abbott initiates pivotal trial for Cephea device, an innovative treatment for mitral heart valve diseasePR NewswireABBOTT PARK, Ill., Oct. 29, 2026 CROWN-MV trial will evaluate the safety and...

Is Abbott (ABT) a Buy as Wall Street Analysts Look Optimistic?

Based on the average brokerage recommendation (ABR), Abbott (ABT) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

Is Most-Watched Stock Abbott Laboratories (ABT) Worth Betting on Now?

Abbott (ABT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Abbott launches whole-genome sequencing Oncodetect molecular residual disease (MRD) test to detect traces of cancer during and after treatment

Abbott launches whole-genome sequencing Oncodetect molecular residual disease (MRD) test to detect traces of cancer during and after treatment Abbott launches whole-genome sequencing Oncodetect molecular residual disease (MRD) test to detect traces of cancer during and after treatmentPR...

Abbott Laboratories vs. UnitedHealth: Does Health Innovation or Health Insurance Make for a Better Stock to Buy?

Key PointsAbbott Laboratories maintains a highly diversified healthcare business spanning medical technology, diagnostics, and nutrition...

Abbott presents new ESMO data showing 30-percent absolute improvement in sensitivity with the whole-genome sequencing Oncodetect test in colorectal cancer

Abbott presents new ESMO data showing 30-percent absolute improvement in sensitivity with the whole-genome sequencing Oncodetect test in colorectal cancer Abbott presents new ESMO data showing 30-percent absolute improvement in sensitivity with the whole-genome sequencing Oncodetect test in...

Abbott's Q3 Earnings Call Focuses on Nutrition Spin-Off and Outlook

Abbott plans to spin off its $8.5B Nutrition business by 2027 while cutting its 2026 sales growth outlook amid diabetes pricing and electrophysiology challenges.

Nasdaq and Small Caps Lead Three Day Surge as Crude Slides and Blue Chips Hold Firm

Nasdaq and Small Caps Lead Three Day Surge as Crude Slides and Blue Chips Hold Firm Nasdaq and Small Caps Lead Three Day Surge as Crude Slides and Blue Chips Hold FirmPR NewswireVANCOUVER, BC, Oct. 21, 2026 VANCOUVER, BC, Oct. 21, 2026 /PRNewswire/ -- Stock Preachers News Commentary - Three...

Abbott Laboratories Q3 2026 Earnings Call Transcript

Abbott Laboratories (NYSE:ABT) reported third-quarter financial results on Wednesday. The transcript from the company's third-quarter earnings call has been provided below.This transcript is brought to you by Benzingaread more...

• Reported GAAP EPS of $1.42 up 9.23% YoY
• Reported revenue of $13.01B up 14.46% YoY
• Abbott projects full-year 2026 comparable sales growth of approximately 6.0%, adjusted diluted EPS of $5.50 to $5.55, and fourth-quarter 2026 adjusted diluted EPS of $1.62 to $1.67; Abbott reaffirms the midpoint and tightens the range.

Abbott's operating and net earnings declined, Nutrition comparable sales fell during 9M26, and third-quarter specified items included approximately $670M for Gill and NEC claim resolutions.

Abbott's new product approvals expand offerings across diabetes, atrial fibrillation and cancer screening; Medical Devices growth was led by Electrophysiology and Rhythm Management, while Key Emerging Markets comparable sales increased 10.9%.

Abbott Laboratories engages in the discovery, development, manufacture, and sale of healthcare products. It operates through the following segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment focuses on branded generic pharmaceuticals that are manufactured worldwide and marketed and sold outside the United States, primarily in emerging markets. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, clinics, physicians' offices, retailers, government agencies, and alternative care testing sites. The Nutritional Products segment oversees the worldwide sale of pediatric and adult nutritional products. The Medical Devices segment offers a broad range of rhythm management, electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, as well as diabetes care and continuous glucose monitoring products. It also provides neuromodulation devices for the management of chronic pain and movement disorders. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.

Abbott Laboratories

ABT, FIG, IP Stocks Fell To 52-Week Lows Today: What's Happening?

Equity

Bearish Sentiment

<ul class="summary-bullets"><li>ABT stock fell to a 52-week low of $90.29 in intraday trading as weak Covid-19 testing and U.S. pediatric nutrition, and other sectoral concerns weighed on its performance.&nbsp;</li><li>FIG stock fell to a 52-week low of $16.60 in Thursday’s intraday session as concerns over Anthropic’s AI design tool continued to linger.&nbsp;</li><li>IP stock fell to a 52-week low of $29.45 after its first-quarter results failed to meet Wall Street expectations.</li></ul><p>Abbott Laboratories (ABT), Figma Inc. (FIG), and International Paper Co. (IP) stocks were among those that hit fresh intraday lows on Thursday as investors grew skeptical over regulatory concerns, emerging competitive threats, and earnings results.</p><p>Shares of ABT fell about 0.6% at the close and IP stock closed down more than 9%. Meanwhile, FIG shares recovered from intraday lows, closing up about 5%.</p><h2 class="st-heading-2">Sectoral Concerns Weigh On Abbott</h2><p>The global healthcare company’s shares fell to a 52-week low of $90.29 in intraday trading, capping two consecutive months of declines.</p><p>Abbott has been facing pressure from declining demand for Covid-19 testing, market-share losses in pediatric nutrition, and other sectoral headwinds. Recent positive developments, including FDA clearance for its AI-powered coronary imaging platform Ultreon 3.0 Software, and positive data from four trials, have failed to meaningfully revive the stock’s performance.</p><p>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/abt">ABT stock</a> has remained in the ‘bearish’ territory over the past 24 hours amid ‘high’ message volumes. ABT shares have declined more than 26% this year.</p><h2 class="st-heading-2">Figma Swings On AI Concerns</h2><p><a href="https://stocktwits.com/symbol/FIG">FIG stock</a> fell to a 52-week low of $16.60 in Thursday’s intraday session before recovering to $17.70 at close. Although the design company has been under pressure over concerns around Anthropic’s artificial intelligence tool, retail investors in the company have largely dismissed concerns.</p><p>Meanwhile, according to Koyfin data, 12 analysts covering the stock have a 12-month average price target of $40.25, representing an upside potential of about 127% from the previous close.</p><p>FIG stock has declined nearly 53% this year, but retail traders on Stocktwits remain ‘bullish’ on the stock.</p><h2 class="st-heading-2">International Paper Declines On Weak Results</h2><p><a href="https://stocktwits.com/symbol/ip">IP stock</a> fell to a fresh 52-week low of $29.45 after it posted first-quarter (Q1) results that disappointed Wall Street and retail investors alike.</p><p>JPMorgan said in a note on Thursday that International Paper's Q1 EBITDA of $677 million was 3% below consensus and below its own guidance of $740 million, according to TheFly. The company’s guidance for the following quarter’s EBITDA was also 25% below consensus estimates at the mid-point. The firm said that the Q1 report was "worse than our negative catalyst watch envisioned."</p><p>JPMorgan has a Neutral rating and $46 price target on International Paper shares. Meanwhile, retail sentiment around the stock was ‘bullish’ at the time of writing. IP stock has lost more than 24% this year.</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

The illustration shows the US flag, cash dollar banknotes and stock market indicators. Top US firms announced record buybacks this year. (Source: Getty Images)

Abbott Laboratories, Figma, and International Paper declined to yearly lows amid market pressures, AI threat, and weak earnings. 

Figma

International Paper Co.

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$106.20
Prev Close	$104.57
Open	$106.15
Dividend Yield	1.92%
50-Day Moving Average	$104.34
Beta	0.19
Avg. Volume	8.58M
PE Ratio	39.21

52-Week High	$132.03
52-Week Low	$81.97
Market Capitalization	$183.77B
EPS (Annual)	$3.72
Price to Book	3.60
Revenue Per Employee	$385,460.87

Feed

News

Sentiment

Earnings

Fundamentals

Info

ABT Fundamentals